It is indicated for patients whose condition is classified NYHA class II-IV, to reduce the risk of cardiovascular death and heart failure hospitalization. More
Orkambi is the first drug approved to treat the underlying cause of CF in people aged 12 years and older who have 2 copies of the F508del mutation. More